What did Smith & Nephew pay for Osiris Therapeutics, Inc.?

Smith & Nephew acquired Osiris Therapeutics, Inc. for $660.0M in 2019 (28.8x EBITDA), equivalent to 4.20x revenue. Target revenue was approximately $157.4M. Target EBITDA was approximately $22.9M.

What does Osiris Therapeutics, Inc. do?

Osiris Therapeutics, Inc. is a medical devices business.

What multiple did Smith & Nephew pay for Osiris Therapeutics, Inc.?

28.8x EBITDA and 4.20x revenue, based on disclosed deal value of $660.0M and disclosed financials.

M&A TRANSACTION · 2019

Osiris Therapeutics, Inc. acquired by Smith & Nephew

$660.0M· 28.8x EBITDA· 4.20x revenue

Target

Osiris Therapeutics, Inc.

Acquirer

Smith & Nephew

Strategic buyer

Disclosed financials at time of acquisition

Revenue

$157.4M

EBITDA

$22.9M

Deal Value

$660.0M

EV/EBITDA

28.8x

Context

This $660.0M acquisition of Osiris Therapeutics, Inc. by Smith & Nephew sits in the medical devices sub-vertical. The 28.8x EBITDA multiple paid in 2019 can be compared against the population median for medical devices transactions of similar size on our Medical Devices valuation hub. Smith & Nephew is acquiring as a strategic buyer; see how strategic acquirers typically price medical devices businesses on our Medical Devices strategic buyer-pool page.

Source

Data sourced from SEC Fairness Opinion — primary source. All figures reflect disclosed values at the time of the acquisition; no estimated or imputed data. Methodology

Value your own medical devices

Get an instant valuation range for your business. Backed by 25,592 real M&A transactions.

Compare your business to the Osiris Therapeutics, Inc. acquisition.

Citation: ExitValue.ai. (2019). Osiris Therapeutics, Inc. acquired by Smith & Nephew. https://exitvalue.ai/deals/osiris-therapeutics-inc-acquired-by-smith-nephew-fairness-opi